SEARCH

SEARCH BY CITATION

Reference

  • Bennett, J.M., Catovsky, D. & Daniel, M.T. (1982) Proposal for the classification of myelodysplastic syndromes. British Journal of Haematology, 51, 189199.
  • Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Annals of Internal Medicine, 103, 620625.
  • Berk P.D., Wasserman, L.R., Fruchtman, S.M. & Goldberg, J.D. (1995) Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Polycythemia Vera and the Myeloproliferative Disorders (ed. by L.R.Wasserman, P.D.Berk & N.I.Berlin), pp. 166194. W.B. Saunders Company, Philadelphia, PA.
  • Brown, D.W, Giles, W.H. & Croft, J.B. (2001) Hematocrit and the risk of coronary heart disease mortality. American Heart Journal, 142, 657663.
  • Chien, S. & Gallik, S. (1995) Rheology in normal individuals and polycythemia vera. In: Polycythemia Vera and the Myeloproliferative Disorders (ed. by L.R.Wasserman, P.D.Berk & N.I.Berlin), pp. 114129. W.B. Saunders Company, Philadelphia, PA.
  • Erikssen, G., Thaulow, E., Sandvik, L., Stormorken, H. & Erikssen, J. (1993) Haematocrit: a predictor of cardiovascular mortality? Journal of Internal Medicine, 234, 493499.
  • Finazzi, G., Caruso, V., Marchioli, R., Capnist, G., Chisesi, T., Finelli, C., Gugliotta, L., Landolfi, R., Kutti, J., Gisslinger, H., Marilus, R., Patrono, C., Pogliani, E.M., Randi, M.L., Villegas, A., Tognoni, G. & Barbui, T. ECLAP Investigators (2005) Acute leukemia in Polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 105, 26642670.
  • Gordeuk, V.R. & Prchal, J.T. (2006) Vascular complications in Chuvash polycythemia. Seminars in Thrombosis and Hemostasis, 32, 289294.
  • Gordeuk, V.R., Sergueeva, A.I., Miasnikova, G.Y., Okhotin, D., Voloshin, Y., Choyke, P.L., Butman, J.A., Jedlickova, K., Prchal, J.T. & Polyakova, L.A. (2004) Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood, 103, 39243932.
  • Irace, C., Ciamei, M., Crivaro, A., Fiaschi, E., Madia, A., Cortese, C. & Gnasso, A. (2003) Hematocrit is associated with carotid atherosclerosis in men but not in women. Coronary Artery Disease, 14, 279284.
  • Landolfi, R. & Marchioli, R. (1997) European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial. Seminars in Thrombosis and Hemostasis, 23, 473478.
  • Landolfi, R., Ciabattoni, G., Patrignani, P., Castellana, M.A., Pogliani, E., Bizzi, B. & Patrono, C. (1992) Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood, 80, 19651971.
  • Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C. & Barbui, T on behalf of the European Collaboration on Low-dose Aspirin in Polycythemia Vera Investigators (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350, 114124.
  • Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G. & Barbui, T. (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of Clinical Oncology, 23, 22242232.
  • Murphy, S. (1995) Megakaryocytes, platelets, and coagulation in the myeloproliferative diseases. In: Polycythemia Vera and the Myeloproliferative Disorders (ed. by L.R.Wasserman, P.D.Berk & N.I.Berlin), pp. 102113. W.B. Saunders Company, Philadelphia, PA.
  • Pearson, T.C. & Messinezy, M. (1996) The diagnostic criteria of polycythemia vera. Leukemia and Lymphoma, 22(Suppl.) 8793.
  • Pearson, T.C. & Wetherley-Mein, G. (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythemia. Lancet, 2, 12191222.
  • Prchal, J.T. (2003) Elevated hematocrit, risk of thrombosis, and polycythemia vera. Blood, 101, 4229.
  • Prchal, J.T. & Beutler, E. (2005) Primary and secondary polycythemias (erythrocytosis). In: Williams Hematology (ed. By M.A.Lichtman & W.J.Williams), pp. 779803. McGraw-Hill Medical Pub., New York, NY.
  • Schafer, A.I. (2006) Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood, 107, 42144222.
  • Sorlie, P.D., Garcia-Palmieri, M.R., Costas, R. & Havlik, R.J. (1981) Hematocrit and risk of coronary heart disease: the Puerto Rico Health Program. American Heart Journal, 101, 456461.
  • Spivak, J.L. (2002) Polycythemia vera: myths, mechanisms, and management. Blood, 100, 42724290.
  • Spivak, J.L., Barosi, G., Tognoni, G., Barbui, T., Finazzi, G., Marchioli, R. & Marchetti, M. (2003) Chronic myeloproliferative disorders. Hematology American Society of Hematology Education Program, 200224.
  • Streiff, M.B., Smith, B. & Spivak, J.L. (2002) The diagnosis and management of polycythemia vera in the era since Polycythemia Vera Study Group: a survey of America Society of Hematology members’ practice patterns. Blood, 99, 11441149.
  • Thorne, S.A. (1998) Management of polycythemia in adults with cyanotic congenital heart disease. Heart, 79, 315316.
  • Vongpatanasin, W., Brickner, M.E., Hillis, L.D. & Lange, R.A. (1998) The Eisenmenger syndrome in adults. Annals of Internal Medicine, 128, 745755.
  • Wehmeier, A., Daum, I., Jamin, H. & Schneider, W. (1991) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Annals of Hematology, 63, 101106.